Strides Hits Pause On Stelis Injectables Investments

Makes A Strong Showing In Q1

Strides has paused further investments in the sterile injectables business under Stelis, citing pandemic-related uncertainty and loss of revenue from ranitidine withdrawal in the US. A prior investment commitment of $40m in Stelis will, however, be fulfilled. Meanwhile, Strides reported a strong first quarter led by non-US markets.

Pause
Strides Suspended Additional Investments In Stelis's Injectables • Source: Shutterstock

More from Strategy

More from Business